The Library
Comparing laboratory costs of smear/culture and Xpert(®) MTB/RIF-based tuberculosis diagnostic algorithms
Tools
Tools
Tools
Naidoo, P., Dunbar, R., du Toit, E., van Niekerk, M., Squire, S. B., Beyers, N. and Madan, Jason (2016) Comparing laboratory costs of smear/culture and Xpert(®) MTB/RIF-based tuberculosis diagnostic algorithms. The International Journal of Tuberculosis and Lung Disease, 20 (10). pp. 1377-1385. doi:10.5588/ijtld.16.0081 ISSN 1815-7920. [ 🗎 Public].
![[img]](http://wrap.warwick.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
WRAP_wms_clinical_trials-110117-r1_laboratory_costs_20160505.pdf - Accepted Version - Requires a PDF viewer. Download (586Kb) |
Official URL: https://doi.org/10.5588/ijtld.16.0081
Abstract
SETTING: Cape Town, South Africa, where Xpert® MTB/RIF was introduced as a screening test for all presumptive tuberculosis (TB) cases.
OBJECTIVE: To compare laboratory costs of smear/culture- and Xpert-based tuberculosis (TB) diagnostic algorithms in routine operational conditions.
METHODS: Economic costing was undertaken from a laboratory perspective, using an ingredients-based costing approach. Cost allocation was based on reviews of standard operating procedures and laboratory records, timing of test procedures, measurement of laboratory areas and manager interviews. We analysed laboratory test data to assess overall costs and cost per pulmonary TB and multidrug-resistant TB (MDR-TB) case diagnosed. Costs were expressed as 2013 Consumer Price Index-adjusted values.
RESULTS: Total TB diagnostic costs increased by 43%, from US$440 967 in the smear/culture-based algorithm (April–June 2011) to US$632 262 in the Xpert-based algorithm (April–June 2013). The cost per TB case diagnosed increased by 157%, from US$48.77 (n = 1601) to US$125.32 (n = 1281). The total cost per MDR-TB case diagnosed was similar, at US$190.14 and US$183.86, with 95 and 107 cases diagnosed in the respective algorithms.
CONCLUSION: The introduction of the Xpert-based algorithm resulted in substantial cost increases. This was not matched by the expected increase in TB diagnostic efficacy, calling into question the sustainability of this expensive new technology.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RB Pathology R Medicine > RC Internal medicine |
||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||
| SWORD Depositor: | Library Publications Router | ||||||
| Library of Congress Subject Headings (LCSH): | Tuberculosis -- Treatment -- Cost effectiveness, Diagnosis, Laboratory | ||||||
| Journal or Publication Title: | The International Journal of Tuberculosis and Lung Disease | ||||||
| Publisher: | International Union against Tuberculosis and Lung Disease,Union Internationale contre la Tuberculose et les Maladies Respiratoires | ||||||
| ISSN: | 1815-7920 | ||||||
| Official Date: | 1 October 2016 | ||||||
| Dates: |
|
||||||
| Volume: | 20 | ||||||
| Number: | 10 | ||||||
| Number of Pages: | 9 | ||||||
| Page Range: | pp. 1377-1385 | ||||||
| DOI: | 10.5588/ijtld.16.0081 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||
| Date of first compliant deposit: | 12 January 2017 | ||||||
| Date of first compliant Open Access: | 1 April 2017 | ||||||
| Funder: | United States. Agency for International Development (USAID) | ||||||
| Grant number: | TREAT TB – Agreement No. GHN -A-00-08-00004-00 |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
